Third Age Health Services (TAH) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
15 May, 2026Executive summary
Achieved significant organic growth in aged residential care (ARC) and general practice, expanding national footprint and increasing ARC patients by 18% year-over-year, now serving 12.4% of NZ's ARC population from 67 facilities.
Revenue grew 35% to $15.15m, with core ARC revenue up 39% and general practice revenue up 30% compared to FY23.
Underlying NPATA rose 148% to $1.71m, and statutory NPAT increased 236% to $1.38m year-over-year.
Investments in digital clinical platforms, workforce development, and process improvement drove operational efficiency and customer satisfaction.
Financial highlights
Revenue: $15.15m, up 35% year-over-year.
Underlying EBIT: $2.61m, up 75% year-over-year; EBIT margin improved to 17.2%.
Statutory NPAT: $1.38m, up 236% year-over-year.
Basic EPS: 13.99 cents, up 220% year-over-year.
Cash and cash equivalents increased to $1.70m; operating cash flow $2.68m.
Ordinary dividends per share doubled to 10.07 cents.
Outlook and guidance
Expecting continued organic revenue and underlying profit growth in FY25, though at a more moderate pace than FY24.
Targeting a long-term dividend payout ratio of 50-60% to support debt repayment and future growth.
Anticipates further benefits from digital investments and process improvements.
Latest events from Third Age Health Services
- NPAT up 115% to $1,154k, with strong revenue, margin, and patient growth.TAH
H1 202516 Jun 2026 - Underlying NPATA up 69% and revenue up 26%, with strong growth in ARC and General Practice.TAH
H2 202516 Jun 2026 - NPAT up 32% and revenue up 13.2% year-over-year, driven by acquisitions and ARC expansion.TAH
H1 202616 Jun 2026 - Q3 FY26 revenue up 23.3% YoY, underlying NPATA up 22.1%, 4.00 cent dividend declared.TAH
Q3 2026 TU16 Jun 2026 - Revenue up 17.9% YoY, underlying NPATA up 25.9%, and total FY26 dividends at 16.00 cents.TAH
H2 202616 Jun 2026 - Q3 FY25 saw strong profit growth, margin expansion, higher dividends, and robust patient gains.TAH
Q3 2025 TU10 Dec 2025 - Strong profit growth and a new fixed dividend policy highlight robust Q1 FY26 performance.TAH
Q1 2026 TU28 Jul 2025 - Revenue and profit surged in Q1 FY25, supported by acquisitions and patient growth.TAH
Q1 2025 TU13 Jun 2025